The role of graft-versus-malignancy reactivity in the effects of allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusion (DLI) for myelodysplastic syndromes is as yet not well established. Clinical data are limited and animal models are scarce. Here, we report on the effects of allogeneic bone marrow transplantation (alloBMT) and DLI in a novel model of irradiation-induced murine myelodysplastic/myeloproliferation syndrome (MD/MPS). Total body irradiation with 8.5 Gy in SJL/J mice gave rise to a lethal wasting syndrome in 60% of mice, characterized by 11 normocellular bone marrow with dysplastic features in erythroid, myeloid and megakaryocytic cell lineages, 21 lymphosplenomegaly with spleens harboring a prominent extramedullary hematopoiesis with erythroid, myeloid and megakaryocytic lineages exhibiting dysplastic features, and foci of dysplastic hematomyelopoiesis in the liver, 31 peripheral thrombocytopenia and 41 evidence of disseminated infection or leukemic transformation in selected animals. This clinicopathological picture was consistent with a murine form of MD/MPS. Syngeneic or allogeneic (BALB/c) T cell-depleted BMT could not prevent the occurrence of lethal MD/MPS. In contrast, DLI at weeks 2-4 after BMT led to restoration of the dysbalanced hematomyelopoiesis. However, severe DLI-induced acute graft-versus-host disease occurred, precluding a survival advantage. We present evidence of the existence of a post-alloBMT DLI-induced graft-versus-MD/MPS effect in murine irradiation-induced MD/MPS.
Introduction
The myelodysplastic syndromes (MDS) encompass a heterogeneous group of hematopoietic stem cell disorders characterized by chronic cytopenias (anemia, neutropenia and thrombocytopenia) and abnormal cellular maturation, evident as dysplasia. Associated risks are infection, bleeding, anemia and a propensity to evolve into acute myeloid leukemia (AML), which is often refractory to standard treatments. 1 A number of patients have both dysplastic and proliferative features at the time of presentation and these are distinguished as having myelodysplastic/myeloproliferative disease (MD/MPS). [1] [2] [3] According to the International Prognostic Scoring System approximately one-third of the patients are classified as low risk and can be managed conservatively, whereas the others are classified as intermediate or high risk and require active therapy. 4 Current treatment options include transfusion of packed cells, drug therapy with immunosuppressants (antithymocyte globulin and cyclosporine), lenalidomide, 5-azacytidine and decitabine, or allogeneic hematopoietic stem cell transplantation (alloHSCT). Reportedly, the response rates for most of the therapeutic drugs used in MDS range from 30% to less than 10%. 5 AlloHSCT confers a significant possibility of cure in low and intermediate-risk 1 MDS patients, but incidences of transplant-related mortality and disease relapse at 5 years have been reported to be as high as 40%. AlloHSCT is therefore not routinely offered to this category of patients. 6, 7 Rather, it is currently reserved for International Prognostic Scoring System intermediate-risk 2 and high-risk patients, who, in addition, have an HLA-matched sibling donor, are less than 60 years of age and have a good or excellent performance status.
Relapse rates after alloHSCT for high-risk MDS are between 15 and 80%, and account for approximately 50% of posttransplant deaths. [7] [8] [9] [10] Intensification of conditioning regimens has been shown to result in an increase of nonrelapse-related morbidity and mortality, and survival benefits were not obtained. 11 In hematological malignancies, such as chronic myelogenous leukemia (CML), alloHSCT aims at establishing graft-versus-malignancy (GvM) effects: it is accepted that this immune-mediated destruction of leukemic cells by grafted T and NK cells is crucial in the prevention of post-transplant relapse. GvM responses are often induced through adoptive immunotherapy with donor lymphocyte infusions (DLIs), 12 given either prophylactically or as salvage therapy for post-transplant leukemic relapse. [13] [14] [15] Considerable variability exists in the susceptibility of different types of leukemia to DLI-induced GvM effects. 15 In MDS, the contribution of DLI-induced GvM reactivity to the therapeutic effects of alloHSCT with consecutive DLI treatments is as yet not well established. Single case reports of MDS patients that relapsed after alloHSCT and showed cytogenetic remission after DLI date from mid 1990s. [16] [17] [18] [19] Since then, several small series of MDS patients have been reported on. They show that post-alloHSCT DLI, given either therapeutically for disease relapse or prophylactically to prevent relapse, can result in complete remission, but that long-term survival is infrequent and is usually precluded by ultimate disease relapse or severe graft-versus-host disease (GvHD). [16] [17] [18] [19] Other than these case reports and small series, clinical data on graft-versus-MDS responses are limited. In addition, animal models of MDS are scarce: although genetically engineered mouse MDS models have been reported on, [20] [21] [22] [23] their importance mainly lies in the study of the molecular basis and pathogenesis of MDS. In particular, GvM effects in MDS have so far not been studied experimentally.
Low-dose total body irradiation (TBI) of SJL/J mice is known to give rise to a late-onset form of AML with low incidence. 24 Here, we report that high-dose TBI of these mice leads to an early onset and lethal syndrome that exhibits characteristics similar to human MD/MPS 2, 25 and is consistent with a murine form of MD/MPS. 21 We studied the effects of allogeneic bone marrow transplantation (alloBMT) and DLI in this novel model of MD/MPS: to the best of our knowledge, we are the first to present direct evidence of the existence of a graft-versus-MD/ MPS effect induced by DLI after MHC-mismatched alloBMT.
Materials and methods

Animals
Animals were purchased from Janvier (Le Genest Saint Isle, France). SJL/J (H-2 s ) female mice 10-12 weeks old were used as recipients and Balb/c (H-2 d ) female mice 6-12 weeks old as donors. Recipients were housed in groups of five in plastic cages, bedded with sawdust and fitted with filter caps. Closed housing units were sterilized prior to use, and animals undergoing transplantation were kept under laminar airflow. Diet consisted of standardized pellet chow and water decontaminated by Ultraviolet irradiation. All experiments were approved by the local ethical commission.
Bone marrow transplantation (BMT)
Recipient SJL/J mice were conditioned with 8.5 Gy TBI using a linear accelerator 18 MEV photons (General Electric, Baden, Switzerland) and a dose rate of 3.9 Gy/min with focus to mid-body distance of 100 cm. One day afterward, recipients were reconstituted with 10 Â 10 6 T cell-depleted donor-type BALB/c bone marrow cells (alloBMT) or 5 Â 10 6 non-T cell-depleted host-type SJL/J bone marrow cells (synBMT), administered intravenously. T-cell depletion was performed as described earlier. 26 
DLI
At specified time points, transplanted mice were given allogeneic DLI or syngeneic lymphocyte infusion. Donor-type spleen tissue was aseptically removed and placed in RPMI 1640 with antibiotics on ice. A single-cell suspension was made and the cells were resuspended at 100 or 200 Â 10 6 cells/ml. Chimeric mice were injected in a tail vein with 250 ml of this cell suspension.
Follow-up of animals
Animals were monitored for weight loss, signs of leukemic disease and survival. At specific time points, peripheral blood was collected to determine complete blood count (CBC) values using a Cell Dyn 3500R (Abbott Diagnostics, Ottignies/LouvainLa-Neuve, Belgium) and the evolution of donor chimerism in different cell lineages by flow cytometry (using the FACStar Plus, Becton Dickinson Biosciences, Erembodegem, Belgium), as described earlier. 27 Monoclonal antibodies used were directed against CD3, CD45R/B220, H-
Histopathology and flowcytometric studies
Moribund animals were sacrificed for histopathological and cytological studies. Peripheral blood and bone marrow smears were prepared and stained with May-Grü nwald-Giemsa. Paraffin-embedded sections of prelevated tissues were stained with hematoxylin and eosin. Histology images were taken with a Zeiss Axioplan 2 microscope (Carl Zeiss AG, Gö ttingen, Germany) equipped with a cooled charge-coupled device camera COHU 4910 (Diagnostic Instruments, Detroit, MI, USA). Original magnifications: Â 4, Â 25 and Â 40. Cytology images were taken using a Leica DM LB2 microscope (Leica Microsystem Belgium, Groot Bijgaarden, Belgium and Nikon HC L3TP camera (Nikon Belux, Brussels, Belgium).
Bone marrow, spleen and liver tissues were prelevated and single cell suspensions prepared for flow cytometric analysis (FACStar Plus) using monoclonal antibodies directed against CD3, CD4, CD8, CD11b (Mac-1) and Gr-1 (Becton Dickinson Biosciences).
Mixed lymphocyte reaction (MLR)
Responder cells (nylon wool-enriched chimeric or control splenocytes) and Mitomycin C-treated (Kyowa Hakko Kogyo, Tokyo, Japan) stimulator cells (host-type splenocytes) were cultured for 5 days, as described earlier. 27 DNA synthesis was assayed by (methyl-3H) thymidine incorporation (Radio Chemi- 
Statistical analysis
The Mann-Whitney U-test was used to estimate the level of statistical significance of difference between groups of the data. The log-rank test was used to estimate the level of significance of the difference in survival between groups (Po0.05 was considered as evidence for statistical significance).
Results
High-dose TBI gives rise to MD/MPS SJL/J mice (H-2K s ) were given 8.5 Gy TBI. From day 21 onwards after TBI, a large proportion of the mice developed weight loss (data not shown) and a wasting syndrome, resulting in 60% mortality on day 80 after TBI ( Figure 1 ). Experiments were terminated at day 80; animals that eventually survived never showed clinical signs of disease. Moribund animals were autopsied and showed prominently enlarged spleens and lymph nodes, and discoloration of the liver (Figures 2a-c) . Histopathological examination of the spleens revealed an expanded red pulp with a consequently reduced white pulp (Figure 2d) . Expansion of the red pulp was associated with the omnipresence of a prominent, dysplastic extramedullary hematomyelopoiesis, which surrounded residual lymphoid B-follicles (Figure 2d ). Dysplastic features were noted in the three hematologic lineages. In the erythroid lineage, erythroid precursors showed megaloblastoid appearance (Figure 2e ). An incomplete maturation arrest with absence of mature granulocytes and a predominance of immature myeloid cells including donut cells was observed in the myeloid lineage (Figure 2f) . Finally, the megakaryocytic lineages showed dysplastic megakaryocytes with hypo-or hyperlobulated nuclei and a tendency to cluster (Figure 2g ), also micromegakaryocytes were present (data not shown). Foci of dysplastic extramedullary hematopoiesis were also found in tissue sections of the liver (data not shown).
Bone marrow biopsies showed normocellularity (Figure 3a) . Bone marrow histology and cytology showed variable combinations of the following: erythroid dyspoiesis as evident from erythroid precursors with megaloblastoid appearance (Figure 3b In selected experiments, animals were sacrificed in the early stage of wasting and CBC was determined. The normal range of CBC values was determined in a group of six age-matched naive SJL mice. Values in experimental animals were considered abnormal if they were lower or higher than the mean value±2 s.d. from the naive control group (Table 1) . In a group of three mice given TBI, all of which developed initial signs of wasting, both leucopenia and thrombocytopenia were documented, whereas hemoglobin and red blood cell count were normal. In other established alloBMT models in our laboratory, 28 we have documented that leucopenia is a common finding in the first 6 weeks after irradiation and alloBMT, whereas neutrophil count, red blood cell count and thrombocyte counts are within the normal range of naive recipient-type mice as early as day 21 after the transplant (unpublished observations). According to the Bethesda guidelines for murine hematological malignancies, 29 these findings are consistent with a murine form of MD/MPS. The condition bears similarity to the genetically determined model described by Futterer et al. 21 Some moribund animals exhibited monomorphic cellular infiltrates in the spleen, morphologically indicative of transformation to acute nonlymphoid leukemia (Figure 2h ), whereas some others showed signs indicative of disseminated infection, such as the presence of dense poly-and mononuclear infiltrates in the liver (Figure 2i ).
Flow cytometric analysis of spleens of diseased mice showed the presence of a large cell population that did not express the lineage-specific markers CD11b, Gr-1, CD3, CD4, CD8 or B220 ( Figure 4 ). This phenotypically lineage-negative cell with a specific fluorescence pattern could not be detected in spleens of naive control mice ( Figure 4 ). The association with the morphologically documented prominent dysplastic hematomyelopoiesis in these spleens indicates that this cell population corresponds with either one or more of the dysplastic cell types that accumulate in the context of the MD/MPS. The absence of lineage-specific cell markers is indicative of a maturation stop, as was seen particularly within the myeloid cell line. Interestingly, the same lineage-negative cell population could be documented in the liver, which corresponds with the morphological presence of foci of dysplastic extramedullary hematopoiesis (data not shown).
As SJL/J mice are known to spontaneously develop B cell nonHodgkin's lymphomas, control naive mice were monitored for several months. 30 None of the control mice died during followup ( Figure 1 ) and histopathological and flowcytometric analysis showed no abnormalities (data not shown).
In conclusion, 8.5 Gy TBI in SJL/J mice leads in a significant proportion of mice to a severe wasting syndrome with characteristics of both myelodysplasia and myeloproliferation, an important mortality rate, and complications such as leukemic transformation and/or infection. This clinicopathological entity is consistent with a murine form of MD/MPS. 21, 29 Irradiation-induced mortality is not due to aplastic bone marrow failure
The absence of hypo-or acellularity in the bone marrow of diseased mice argues against the development of radiation- Figure 1 Survival of SJL/J mice after TBI, synBMT, alloBMT and alloBMT/DLI. Evolution of the survival of SJL/J mice after TBI only (~), synBMT (.), alloBMT (') and alloBMT/DLI (m). As a control, untreated host SJL/J mice (K) were followed. Survival curves are shown from a total of 10 (TBI), 23 (synBMT), 20 (alloBMT), 30 (alloBMT/DLI) and 19 (naive SJL/J mice). Results are shown from four similarly designed experiments: all groups were tested together in the four experiments (n ¼ 2-6 per group). *Po0.05 for comparison between 'SJL/J control animals' and all other groups, all other comparisons were not significantly different (log-rank test). AlloBMT, allogeneic bone marrow transplantation; DLI, donor lymphocyte infusion; TBI, total body irradiation.
induced toxic bone marrow failure. To definitively prove that the wasting syndrome and mortality were not caused by aplastic bone marrow failure, we performed syngeneic BMT (synBMT) using 5 Â 10 6 non-T cell-depleted SJL/J bone marrow cells in 8.5-Gy-irradiated SJL/J mice. The majority of these mice equally developed a wasting syndrome, of which the mortality rate (70% mortality on day 80, Figure 1 ) and the clinicopathological features were identical to those seen in TBI-treated mice (Figures  2a-h) . In a selected experiment, two of four animals showed early signs of wasting and CBC analysis in these animals showed leucopenia and thrombocytopenia (Table 1) . Flow cytometry equally revealed the lineage-negative cell population in spleens and livers (Figure 4a ).
These data confirmed that the irradiation-induced wasting syndrome and mortality are not caused by radiation-induced bone marrow aplasia.
AlloBMT does not prevent the development of MD/MPS
The effect of alloBMT was studied on the incidence and course of irradiation-induced MD/MPS: 10 7 T cell-depleted BALB/c (H-2K d ) bone marrow cells were infused intravenously in 8.5-Gy-irradiated SJL/J mice, 1 day after irradiation. T cells were removed from the graft to prevent the development of acute GvHD. AlloBMT led to the progressive development of mixed (o ( Â 400)) Normal maturation in spleen of the erythroid and myeloid cell lines, and presence of nondysplastic megakaryocytes (circle, octagon, square). AlloBMT, allogeneic bone marrow transplantation; DLI, donor lymphocyte infusion; TBI, total body irradiation; GvHD, graft-versus-host disease. (Figure 5a ) and B-cell chimerism (data not shown), indicating effective allogeneic engraftment.
GvMD/MPS
From day 21 onwards after alloBMT, a large proportion of the mice developed weight loss and wasting, resulting in 40% mortality on day 80 after transplantation ( Figure 1 ). The survival curve was similar to that of TBI-treated and synBMT mice. In addition, macroscopic, histopathological, cytological and flowcytometric studies confirmed that alloBMT animals suffered from the same MD/MPS entity as the clinically ill TBI and synBMT mice (Figures 2 and 3) . Surviving animals appeared healthy at all time points.
Acute GvHD was not involved in the observed illness of alloBMT animals. This was evident from the following observations. First, the frequencies of donor-anti-host alloreactive T cells (identified on the basis of their expression of the TCRVb8.3 þ -chain 31, 32 ) were sequentially determined in peripheral blood of alloBMT animals and were shown to remain low throughout the follow-up period (Figure 5b ), indicating that donor-anti-host T cells do not expand in vivo. Second, histopathological signs typical of acute GvHD were not seen in extensive histopathological studies (data not shown). Instead, spleens and livers showed features typical of MD/MPS (Figures 2d-h) . Third, spleen cells of diseased alloBMT animals, obtained 6-8 weeks after alloBMT, failed to mount a proliferative response when stimulated with host-type splenocytes in MLR (mean SI 1.6±0.01 s.e.m. (n ¼ 3), Figure 6 ).
These data indicate that, although BALB/c MHC-mismatched alloBMT leads to allogeneic engraftment, it can neither prevent the development of the irradiation-induced MD/MPS nor attenuate its course.
DLI reverses the MD/MPS but results in severe GvHD
To explore the potential of post-transplant DLI to arrest, attenuate or reverse the development of the MD/MPS, alloBMT animals received 25-50 Â 10 6 donor-type splenocytes at 2-4 weeks after transplantation (alloBMT/DLI). From day 7 onwards after DLI, all alloBMT/DLI-mice exhibited weight loss (data not shown) and cachexia, resulting in 50% mortality on day 80 after transplantation, and the kinetics of the mortality curve were GvMD/MPS effect after DLI post-allogeneic hematopoietic stem cell transplantation B Sprangers et al Figure 4 Flowcytometric analysis of spleen cells in TBI, synBMT, alloBMT and alloBMT/DLI animals. Two-color flow cytometry was performed on splenocyte cell suspensions with stainings for CD11b, Gr-1, CD3, B220, CD4 and CD8. Examples are shown from an alloBMT animal (middle row (example representative for all animals from the TBI, synBMT and alloBMT group)), an alloBMT/DLI mouse (lower row) and a naive SJL/J mouse (upper row). Gating of R1 on forwardFside scatter plots (left) defines the viable cell population, excluding red blood cells and debris. Dot plots for antigen-specific stainings (2nd-4th column) are gated in R1; percentages indicate the frequency (within R1) of specific cell populations, quantified by drawing rectangular gates. AlloBMT, allogeneic bone marrow transplantation; DLI, donor lymphocyte infusion; TBI, total body irradiation.
similar to those in TBI, synBMT and alloBMT mice (Figure 1 ). However, in contrast to the latter three groups, clinically ill alloBMT/DLI mice exhibited hunchback and ruffled fur, which are clinical signs typical of acute GvHD. This was evident from the following observations. First, liver sections no longer showed dysplastic extramedullary hematopoiesis but rather contained infiltrates composed of small lymphoid elements (Figure 2m ), and intestinal walls showed inflammatory infiltrates adjacent to the epithelium (data not shown): these observations are typical for acute GvHD. Second, spleen cells from alloBMT/ DLI animals, obtained 2-4 weeks after DLI, mounted a strong anti-host proliferative response in ex vivo MLR, in contrast to the absent response of alloBMT animals ( Figure 6 ). Third, sequential flowcytometric studies showed an expansion of peripheral blood host-reactive TCR-Vb8.3 þ CD3 þ cells, while frequencies remained low in alloBMT animals that exhibited no further signs or symptoms of acute GvHD (Figure 5b) . 31, 32 In a separate experimental set-up, animals were inspected daily and when critically ill, they were sacrificed and used for histopathological and flowcytometric studies: this resulted in the Effect of DLI on incidence of MD/MPS. Following alloBMT and alloBMT/DLI, animals were inspected daily and when critically ill, were sacrificed and used for histopathological and flowcytometric studies: this resulted in the sacrifice of 1-3 animals of each group at the indicated time points. MD/MPS was diagnosed on the basis of the presence of typical characteristics on flow cytometry and histopathology in spleens, livers and bone marrow. Curves show the cumulative incidence of MD/MPS in alloBMT (n ¼ 21') and alloBMT/DLI animals (n ¼ 25m), as obtained in seven identically designed experiments. *Po0.05, log-rank test. MD/MPS, myelodysplastic/myeloproliferation syndrome; alloBMT, allogeneic bone marrow transplantation; DLI, donor lymphocyte infusion.
sacrifice of 1-3 animals of each group on 12 separate time points between day 23 and 78 ( Figure 7 ). These studies showed that, in addition to a different clinical picture, the pathological and cell phenotypic features of the wasting syndrome in alloBMT/DLI animals were different. First, autopsy of moribund animals invariably showed small spleens and lymph nodes, and macroscopically normal livers (data not shown). Second, histopathological studies showedFcontrary to animals in all the three other treatment groupsFthat the splenic white pulp was atrophic and fibrotic (Figure 2n) , and that the extramedullary hematopoiesis harbored by the red pulp was proportional and morphologically intact with the normal, nondysplastic maturation of the erythroid and myeloid cell lineages and nondysplastic megakaryocytes (Figure 2o) . Third, the flowcytometric lineage-negative cell population, as one of the typical characteristics of the MD/MPS, could no longer be detected in spleens (Figure 4) or livers (data not shown) . On the basis of these results, we determined the cumulative incidence of MD/ MPS (defined as the presence of the characteristic abnormalities on flowcytometry and/or pathology, as described above), and found that DLI resulted in 4% cumulative incidence of the MD/ MPS, as opposed to an incidence of 100% in alloBMT chimeras that become ill ( ¼ 60%) after alloBMT ( Figure 7) .
Finally, as a control, we determined whether recipient-type lymphocytes were equally capable of preventing or reversing the MD/MPS disorder. To this end, a group of five synBMT mice were given 50 Â 10 6 syngeneic splenocytes (syngeneic lymphocyte infusion). Three of five mice developed wasting disease around day 32 and 36. CBC analysis of these animals showed typical leucopenia and thrombocytopenia (Table 1) , and histology and cytology showed MD/MPS as seen in TBI, synBMT and alloBMT mice (Figures 2 and 3) .
We conclude that post-alloBMT DLI in this model gives rise to acute and often lethal GvHD, and that the associated resolution of the MD/MPS indicates the existence of an immune-mediated anti-MD/MPS effect.
Discussion
Although clinical experience with alloHSCT and DLI suggests that post-transplant remission from MDS may result from a GvM effect, data are scarce and the existence of an immune-mediated graft-versus-myelodysplasia effect has not been proven. A limited number of genetically engineered mouse models of MDS exists, and these were developed with the objective of unraveling the molecular etiology and pathogenesis of MDS. [20] [21] [22] [23] Here, we describe a radiation-induced model of MD/MPS in mice, which, in addition, is suitable for the study of allograft-mediated immune effects. Using this model, we were able to experimentally demonstrate that MD/MPS is susceptible to DLI in the context of MHC-mismatched alloBMT. Unfortunately, as is typically seen with this type of DLI, the DLI-induced anti-MD/MPS effect was associated with severe acute GvHD, which precluded a survival advantage, but our findings support alloreactivity as an underlying mechanism of DLI-induced anti-MD/MPS effect.
In human MDS, several cytogenetic abnormalities, (associated) altered expression of genes and gene deletions have been described. 33 In recently published mouse studies, it was shown that deletion of AML1, transgenic expression of EVI1 or NUP98-HOXD13, as well targeting of Dido lead to the development of a hematopathological picture similar to human MDS or MD/MPS. [20] [21] [22] [23] These recent studies have provided key information on the molecular basis of MDSFin particular, how selected genetic abnormalities may lead to defects in proliferation and differentiation and to leukemic transformation in MDS and MD/MPS. [20] [21] [22] [23] Our model of radiation-induced MDS may be particularly suited for the study of the therapeutic value of alloHSCT and DLI.
The diagnosis of murine MD/MPS was evident from the observed hematological, cytological and histological findings. Peripheral thrombocytopenia and dysplastic changes in the different cell lineages are consistent with murine 'myelodysplastic syndrome', whereas proliferative features such as extramedullary hematopoiesis and splenomegaly are consistent with the diagnosis of murine 'myeloproliferation'. 2, 29 In addition to thrombocytopenia, leucopenia was documented in all animals. Neutropenia rather than leucopenia is a recognized feature of murine MDS. 29 Leucopenia and thrombocytopenia may occur as a result of recent irradiation and BMT. In other alloBMT mouse models, 28 we have documented that leucopenia is a common finding in the first 6 weeks after BMT, whereas neutrophil counts, red blood cell counts and thrombocyte counts are within the normal range of naive recipient-type mice within 3 weeks after the transplant (unpublished observations). However, in the current model, the imbalance between an exaggerated myelopoiesis in the spleen and the persistent leucopenia in the periphery reflects the maturation arrest in the myeloid lineage and further supports the diagnosis of myeloproliferation and myelodysplasia. In a subset of animals, histopathological signs of disseminated infection were documented, whereas in some other mice, monomorphic infiltrates indicative of leukemic transformation were seen, indicating the development of two other well-known features of the human form of MDS, in case of severe infections and progression to acute nonlymphoid leukemia. The clinicopathological picture is consistent with that seen in the recently reported MD/MPS condition in Dido gene-targeted mice. 21 Although a high-irradiation dose was used, the dose of 8.5 Gy is generally not myeloablative in other mouse strains. Bone marrow failure, as a cause of death in the observed wasting syndrome was therefore unlikely. This was supported, first, by the observation that bone marrow sections showed normocellularity at the moment that mice succumbed to the disease, and, second, that syngeneic BMT was unable to rescue irradiated mice from the MD/MPS condition. Engraftment cannot be documented in a syngeneic context, but since good engraftment was obtained with alloBMT, and since syngeneic bone marrow usually engrafts more easily than allogeneic bone marrow, graft failure is an unlikely explanation for the failure of synBMT to rescue mice from MD/MPS. Rather, the data indicate that TBI induces a myelodysplastic/myeloproliferation disorder that evolves independently of the engrafting healthy bone marrow cells. It appears that in these mice, the competition between healthy donor cells and irradiated recipient hematopoietic cells that evolve into MD/MPS is not strong enough to rescue the mice. In contrast, it is the alloreactivity of nontolerant allogeneic donor-type lymphocytes that can counteract pathological recipient myelohematopoiesis, providing proof of principle of a graft-versus-MD/MPS effect. Finally, infusion of syngeneic lymphocyte infusion could not prevent the occurrence of the MD/MPS disorder, further indicating that the effect seen after DLI cannot be attributed to competition of healthy with dysplastic cells, but is intrinsically related to the occurrence of alloreactivity.
The MD/MPS syndrome was associated with the appearance on flowcytometric studies of a lineage-negative cell population with a specific fluorescence pattern. The association with the morphologically documented prominent dysplastic hemato-myelopoiesis in these spleens indicates that this population corresponds with either one or more of the dysplastic cell types and that the absence of lineage-specific markers indicates maturation stop and dysplasia. This was further supported by the observation that both the lineage-negative population and the dysplastic hematomyelopoiesis disappeared after DLI. It is noted that in other models, we have shown earlier that after high-dose irradiation and allo-or synBMT, a transient expansion occurs of CD11b þ Gr1 þ early myeloid cells. 27 This was associated neither with disruption of the splenic architecture nor with hematological or morphological evidence of myelodysplasia (unpublished observations), and these mice remained completely healthy. A relative increase of these CD11b þ Gr1 þ myeloid cells was equally seen in alloBMT animals in the current model, and appeared to be even more pronouncedFdue to GvHD-related lymphopeniaFin alloBMT animals given DLI (Figure 2i) .
The rationale to test whether high-dose TBI of SJL/J mice would lead to myeloid malignant disease was based on the previously published observation that low-dose TBI (1.5-3 Gy) in this mouse strain gives rise to a late-onset and low-incidence form of AML. 24 These studies showed that a radiation-induced defect on chromosome 2 functions as a differentiation-blocking step, leading to an immature myeloid lineage, 34 while additional administration of corticosteroids promoted AML development by providing a proliferative stimulus and/or survival advantage. 35 Rather than giving rise to an accelerated onset and/or elevated incidence of such a primary malignant myeloid disease, high-dose TBI in our model led to the observed dysplastic/proliferative disorder in which leukemic transformation merely seemed to occur as a complication. Future work will indicate whether the chromosomal defects of the SJL/J radiationinduced AML, or one of the molecular defects described in known genetically engineered mouse MDS or MD/MPS models, [20] [21] [22] [23] are involved in the current model. Animals that eventually survived after TBI with or without syn-or alloBMT never showed clinical signs of disease. It is as yet undetermined whether they suffered from mild, nonlethal disease only or whether they did not develop disease at all. Although these questions are the subject of future studies, in the present study we chose to explore the potential therapeutic effects of alloBMT and DLI in the novel model of MD/MPS.
We performed alloBMT to evaluate the curative potential of allografting in this murine MD/MPS and to create a platform, which allows adoptive cellular immunotherapy. AlloBMT did not have a significant effect on the incidence and mortality of the clinicopathological MD/MPS entity. In contrast, DLI resulted in the restoration of the imbalanced hematomyelopoiesis, with disappearance of the lineage-negative cell population and of the dysplastic features. However, this immune-mediated graftversus-MD/MPS effect did not result in a survival advantage: instead of the typical MD/MPS, DLI animals developed the clinicopathological entity typical for acute GvHD. The close association between GvM effects and GvHD is well known and documented both in patients and in experimental models. 36 Although DLIs can establish potent GvM effects, GvHD occurs in 33-61% of cases and therefore remains a cause of significant post-DLI morbidity and mortality. 37 However, key advances have been made in the elucidation of the immune mechanisms of the GvM effects, particularly for leukemias, and experimental approaches to obtain graft-versus-leukemia responses without GvHD are being developed, some of which have entered clinical practice. 36, 38, 39 Clinical and experimental data indicate that lymphohematopoietic graft-versus-host reactions crucially contribute to graft-versus-leukemia, [40] [41] [42] and it has been shown in mouse models that these require the presence of host-type antigen-presenting cells. In fact, elegant mouse studies have demonstrated differential roles for host-type antigen-presenting cells present within the lymphohematopoietic system, and those residing within the GvHD-target tissues in mediating graftversus-leukemia and GvHD, providing a theoretical basis for the induction of anti-leukemic responses without GvHD. 42 Future studies are directed at exploring whether modified DLI regimens would allow separation of graft-versus-MD/MPS effects from GvHD.
In summary, we describe a novel model of radiation-induced MD/MPS, in which alloHSCT followed by DLI effectuates a potent alloreactivity-mediated graft-versus-MD/MPS effect, although the potential beneficial effect on survival is overruled by severe GvHD. This is in concordance with the reported clinical experience with DLI for MDS. Although limited in number, clinical studies so far indicate that DLI can give rise to remission, but that therapeutic responses are either incomplete or complicated by GvHD. [16] [17] [18] [19] In this experimental model, we chose an aggressive DLI regimen to obtain sufficient alloreactivity and anti-tumor reactivity, and expectedly, lethal GvHD invariably occurred. In the clinical setting, alloHSCT and DLI strategies are designed to induce GvM reactivity with minimal risk for GvHD. This experimental model is suited to explore how DLI can be refined as an immunotherapeutic strategy for murine MD/MPS, and to define the mechanisms involved.
